Breakthroughs in cancer immunotherapy show promise in addressing aggressive and treatment-resistant tumors. Researchers unveiled a biodegradable scaffold delivering TLR7/8 agonists that eradicated glioblastoma in preclinical models. A study identified tumor-associated carbohydrate antigen targeting lectins with high specificity, enhancing pan-cancer immunotherapy potential. Investigations into myeloid immune cells in pediatric liver cancer revealed immunotherapy targets. Additionally, induced mesenchymal stem cells are emerging as innovative delivery systems for ovarian cancer treatments.